MedTrace Logo

Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

NCT04427072 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2025-05-16

Study results available
· View outcomes & findings →

Summary

The purpose of the study was to learn whether the study drug (capmatinib) helps to control lung cancer better compared to a single agent chemotherapy (docetaxel) and whether it is safe when given to patients suffering from a particular type of lung cancer. This type of cancer is called non-small cell lung cancer (NSCLC) with certain specific genetic alterations (called mutations) of a gene called MET, within a specific part of the gene called exon 14.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Capmatinib

400 mg, capmatinib tablets, administered orally twice daily

DRUG

Docetaxel

Docetaxel 75 mg/m\^2 by intravenous infusion every 21 days

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-25
Primary Completion
2023-02-15
Completion
2023-11-06

Countries

  • Belgium
  • Brazil
  • Bulgaria
  • France
  • Germany
  • Hungary
  • India
  • Italy
  • Lithuania
  • Malaysia
  • Netherlands
  • Portugal
  • Russia
  • South Africa
  • South Korea
  • Spain
  • Thailand
  • Vietnam

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04427072 on ClinicalTrials.gov